Latest News for: subtypes

Edit

Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical utility of CELLSEARCH® CTC enumeration to guide treatment decisions in a specific metastatic breast cancer subtype

PR Newswire 22 Dec 2025
CTC count is a standalone predictive biomarker, independent of clinical risk factors and circulating tumor DNA. BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., Dec ... Based on their CTC level, patients were classified into two prognostic groups ... About MSB ... 21%.
Edit

Structural insights into nonpeptide antagonist inhibition of somatostatin receptor subtype 5

PNAS 19 Dec 2025
SignificanceThis study reveals the high-resolution structures of the ...
Edit

TRADE DATE CUSIP SETTLEMENT DATE MATURITY DATE NEXT PAY DATE CALL TYPE DESC CALL STYLE DESC RATE TYPE SUBTYPE DESC NEXT CALL DATE COUPON PCT BANK PAR (Form 8-K) (Federal Home Loan Bank of New York)

Public Technologies 16 Dec 2025
). TRADE DATE. CUSIP. SETTLEMENT DATE. MATURITY DATE. NEXT PAY DATE. CALL TYPE DESC. CALL STYLE DESC. RATE TYPE SUBTYPE DESC. NEXT CALL DATE. COUPON PCT. BANK PAR. 12/10/2025. 3130B8WK4. 12/11/2025. 1/8/2027. 6/8/2026. Optional Principal Redemption. Bermudan ... 6/8/2026.
Edit

Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025

PR Newswire 12 Dec 2025
-       Data supports the continued development of ATNM-400 as a monotherapy or combination therapy to address multiple breast cancer subtypes with limited treatment options ... Potent Efficacy Across Breast Cancer Subtypes.
Edit

Novel breast cancer therapy reduces risk of recurrence for most common subtype of breast cancer, study shows (UCLA - University of California - Los Angeles)

Public Technologies 10 Dec 2025
The finding points to a potential new treatment option for the most common subtype of breast cancer, which accounts for roughly 70% of all cases and is most often diagnosed at Stage 1, 2 or 3.
Edit

Today in Cell, we published new research showing how AI can help accelerate cancer discovery. With GigaTIME, we can now simulate spatial proteomics from routine pathology slides, enabling population-scale analysis of tumor microenvironments across dozens of cancer types and hundreds of subtypes. [See more.] (Microsoft Corporation)

Public Technologies 09 Dec 2025
). The text version of this document is not available ... Disclaimer ... (noodl. 128284982) .
Edit

Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market (Lunai Bioworks Inc)

Public Technologies 09 Dec 2025
Precision Parkinson's Disease Subtypes Via Proteomic & Clinical Integration ... success for subtype-specific therapeutics. Subject-level analyses revealed three outcome-linked patient subtypes.
Edit

Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market

PR Newswire 09 Dec 2025
Precision Parkinson's Disease Subtypes Via Proteomic & Clinical Integration ... success for subtype-specific therapeutics. Subject-level analyses revealed three outcome-linked patient subtypes.
Edit

Distinguishing subtypes of endothelial cells in the mouse aorta

PNAS 04 Dec 2025
... analysis, distinct subtypes of endothelial cells (ECs) were ...
Edit

Taiho Oncology Europe announces the launch of Lytgobi®▼ (futibatinib) in the United Kingdom for eligible adult patients with a previously treated subtype of locally advanced or metastatic cholangiocarcinoma1

Pharmiweb 03 Dec 2025
Lytgobi (futibatinib) marks the first medicine launched by Taiho Oncology Europe in the UK2. BAAR, Switzerland--(BUSINESS WIRE)--For United Kingdom (UK) Trade and Medical Media Only ... Peter Foertig, General Manager of Taiho Oncology Europe ... References ... .
Edit

Structural insights into the G-protein subtype selectivity revealed by human sphingosine-1-phosphate receptor 3–Gq complexes

PNAS 18 Nov 2025
.
Edit

Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy

Nasdaq Globe Newswire 06 Nov 2025
Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABAA α2,3 receptor positive allosteric modulator ... .
Edit

Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator

Enid News & Eagle 06 Nov 2025
Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABAAα2,3 receptor positive allosteric modulator ... .
Edit

Protective Microglia Subtype Offers Potential New Therapeutic Pathway in Alzheimer’s Disease (Mount Sinai Health System Inc)

Public Technologies 06 Nov 2025
) Press Release. Protective Microglia Subtype Offers Potential New Therapeutic Pathway in Alzheimer's Disease. International research team identifies distinct population of neuroprotective immune cells of the central nervous system. Newsroom ... Goate ... Tags.
Edit

New Analysis of 13,560 Patients Demonstrates DecisionDx�-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be ...

Nasdaq Globe Newswire 24 Oct 2025
Castle is presenting data on DecisionDx�-Melanoma and its pipeline atopic dermatitis (AD) test at the 25th Annual Fall Clinical Dermatology Conference ... .

Article Search

tools
×
×
×
×